Is there a legitimate role for the therapeutic use of cannabinoids for symptom management in chronic kidney disease?

Journal of Pain and Symptom Management

Volumn 41, Issue 4, 2011, Pages 768-778

  Davison, Sara N ^a   Davison, Joseph S ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

cannabinoids; End stage renal disease; marijuana; pain; symptom management

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; ENDOCANNABINOID; LEVONANTRADOL; NABILONE; OPIATE;

ABDOMINAL DISTENSION; AGITATION; ANOREXIA; ANXIETY DISORDER; APHTHOUS STOMATITIS; ARTERY STEAL SYNDROME; ARTICLE; BLURRED VISION; BRADICARDIA; BRADYCARDIA; CACHEXIA; CANCER PAIN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DEPRESSION; CHEILITIS; CHRONIC KIDNEY DISEASE; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIZZINESS; DRUG METABOLISM; GASTROESOPHAGEAL REFLUX; HEART PALPITATION; HUMAN; HYPOTENSION; INSOMNIA; INTOXICATION; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LIBIDO DISORDER; LOW BACK PAIN; MEDICOLEGAL ASPECT; NAUSEA; NAUSEA AND VOMITING; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; OSTEOMYELITIS; OSTEOPOROSIS; PANIC; PARANOIA; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SIDE EFFECT; STOMACH PARESIS; SYMPTOM; TACHYCARDIA; TOXICITY; UPPER ABDOMINAL PAIN; UREMIC POLYNEUROPATHY; XEROSTOMIA;

ANALGESICS; CANNABINOIDS; CANNABIS; ENDOCANNABINOIDS; HUMANS; KIDNEY FAILURE, CHRONIC; PAIN; QUALITY OF LIFE; RECEPTORS, CANNABINOID;

EID: 79954422274     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2010.06.016     Document Type: Article

References (47)

1. S.N. Davison Pain in hemodialysis patients: prevalence, cause, severity, and management Am J Kidney Dis 42 2003 1239 1247 (Pubitemid 37486768)
2. S.D. Weisbord, L.F. Fried, and R.M. Arnold Prevalence, severity, and importance of physical and emotional symptoms in chronic hemodialysis patients J Am Soc Nephrol 16 2005 2487 2494 (Pubitemid 41725068)
3. F.E. Murtagh, J. Addington-Hall, and I.J. Higginson The prevalence of symptoms in end-stage renal disease: a systematic review Adv Chronic Kidney Dis 14 2007 82 99 (Pubitemid 46014531)
4. S.N. Davison, G.S. Jhangri, and J.A. Johnson Longitudinal validation of a modified Edmonton Symptom Assessment System (ESAS) in haemodialysis patients Nephrol Dial Transplant 21 2006 3189 3195 (Pubitemid 44567092)
5. S.N. Davison, G.S. Jhangri, and J.A. Johnson Cross-sectional validity of a modified Edmonton Symptom Assessment System in dialysis patients: a simple assessment of symptom burden Kidney Int 69 2006 1621 1625
6. T. Saini, F.E. Murtagh, and P.J. Dupont Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease Palliat Med 20 2006 631 636
7. K. Abdel-Kader, M.L. Unruh, and S.D. Weisbord Symptom burden, depression, and quality of life in chronic and end-stage kidney disease Clin J Am Soc Nephrol 4 2009 1057 1064
8. S.S. Patel, V.S. Shah, R.A. Peterson, and P.L. Kimmel Psychosocial variables, quality of life, and religious beliefs in ESRD patients treated with hemodialysis Am J Kidney Dis 40 2002 1013 1022 (Pubitemid 35265482)
9. V. Maida Cannabinoid-based therapies in supportive oncology: growing evidence for a broad role in symptom management Oncol Exch 6 2007 22 28
10. M. El Sohly Chemical constituents of cannabis F. Grotenhermen, E. Russo, Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential 2002 The Haworth Press, Inc Binghamton, NY 27 36
11. R.G. Pertwee Cannabinoid pharmacology: the first 66 years Br J Pharmacol 147 Suppl 1 2006 S163 S171
12. R.G. Pertwee Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond Addict Biol 13 2008 147 159 (Pubitemid 351698890)
13. I. Grant, and B.R. Cahn Cannabis and endocannabinoid modulators: therapeutic promises and challenges Clin Neurosci Res 5 2005 185 199 (Pubitemid 41671147)
14. R.G. Pertwee The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin Br J Pharmacol 153 2008 199 215
15. R. Mechoulam, M. Peters, E. Murillo-Rodriguez, and L.O. Hanus Cannabidiol - recent advances Chem Biodivers 4 2007 1678 1692 (Pubitemid 47377200)
16. A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, and F.S. Guimaraes Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Braz J Med Biol Res 39 2006 421 429
17. R. Mechoulam, L.A. Parker, and R. Gallily Cannabidiol: an overview of some pharmacological aspects J Clin Pharmacol 42 2002 11S 19S (Pubitemid 35205041)
18. B.S. Basavarajappa Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity Curr Neuropharmacol 5 2007 81 97 (Pubitemid 47019423)
19. M. Duncan, J.S. Davison, and K.A. Sharkey Review article: endocannabinoids and their receptors in the enteric nervous system Aliment Pharmacol Ther 22 2005 667 683 (Pubitemid 41475329)
20. S. Van, M. Duncan, and P.J. Kingsley Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 310 2005 329 332 (Pubitemid 41457202)
21. P. Anand, G. Whiteside, C.J. Fowler, and A.G. Hohmann Targeting CB2 receptors and the endocannabinoid system for the treatment of pain Brain Res Rev 60 2009 255 266
22. 2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats Am J Physiol Gastrointest Liver Physiol 295 2008 978 987
23. A.N. Akopian, N.B. Ruparel, N.A. Jeske, A. Patwardhan, and K.M. Hargreaves Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia Trends Pharmacol Sci 30 2009 79 84
24. P. Pacher, S. Batkai, and G. Kunos The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol Rev 58 2006 389 462 (Pubitemid 44394908)
25. K.D. Patel, J.S. Davison, Q.J. Pittman, and K.A. Sharkey Cannabinoid CB2 receptors in health and disease Curr Med Chem 17 2010 1393 1410
26. V.E. Mendizabal, and E. Adler-Graschinsky Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions Br J Pharmacol 151 2007 427 440 (Pubitemid 46905012)
27. J.E. Schlosburg, S.G. Kinsey, and A.H. Lichtman Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation AAPS J 11 2009 39 44
28. J.Z. Long, W. Li, and L. Booker Selective blockade of 2-anachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat Chem Biol 5 2009 37 44
29. A.S. Rice Should cannabinoids be used as analgesics for neuropathic pain? Nat Clin Pract Neurol 4 2008 654 655
30. F.A. Campbell, M.R. Tramer, and D. Carroll Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review BMJ 323 2001 13 16 (Pubitemid 32681998)
31. M. Iskedjian, B. Bereza, A. Gordon, C. Piwko, and T.R. Einarson Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Curr Med Res Opin 23 2007 17 24 (Pubitemid 46191666)
32. J.R. Johnson, M. Burnell-Nugent, and D. Lossignol Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain J Pain Symptom Manage 39 2010 167 179
33. K.A. Sharkey, L. Cristino, and L.D. Oland Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret Eur J Neurosci 25 2007 2773 2782 (Pubitemid 46888837)
34. S. Van, L.D. Oland, K. Mackie, J.S. Davison, and K.A. Sharkey Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets Am J Physiol Gastrointest Liver Physiol 285 2003 G566 G576
35. S. Van, L.D. Oland, and W. Ho Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret Gastroenterology 121 2001 767 774 (Pubitemid 32959386)
36. M. Rocha, S. Stefano, R. Cassia Haiek, R. Oliveira, and D. Da Silveira Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis Eur J Cancer Care 17 2008 431 443
37. M. Tramer, D. Carroll, and F.A. Campbell Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review BMJ 323 2009 2 3
38. E. Meiri, H. Jhangiani, and J. Vredenburgh Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting J Clin Oncol 23 2005 8018
39. L.A. Parker, M. Kwiatkowska, and R. Mechoulam Delta-9- tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting Physiol Behav 87 2006 66 71 (Pubitemid 41797723)
40. GW Pharma Ltd. Product monograph - Sativex, 2008.
41. D.R. Blake, P. Robson, M. Ho, R.W. Jubb, and C.S. McCabe Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis Rheumatology (Oxford) 45 2006 50 52 (Pubitemid 43033874)
42. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 65 2005 812 819 (Pubitemid 41362120)
43. D.J. Rog, T.J. Nurmikko, and C.A. Young Oromucosal delta9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial Clin Ther 29 2007 2068 2079 (Pubitemid 350218115)
44. J.S. Berman, C. Symonds, and R. Birch Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 112 2004 299 306 (Pubitemid 39550730)
45. J.E. Beal, R. Olson, and L. Lefkowitz Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia J Pain Symptom Manage 14 1997 7 14 (Pubitemid 27287406)
46. J.C. Szepietowski, T. Szepietowski, and A. Reich Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study Acta Dermatovenerol Croat 13 2005 97 103 (Pubitemid 41008254)
47. G.W. Neff, C.B. O'Brien, and K.R. Reddy Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease Am J Gastroenterol 97 2002 2117 2119